Background

In 1949, Georgeanna Jones, MD, first described luteal phase deficiency (LPD). [1] The
inadequate secretory transformation of the endometrium, resulting from deficient
progesterone production, has been implicated in both infertility and recurrent pregnancy loss.
[2, 3]
LPD has been the subject of much debate among specialists in the field of reproductive
endocrinology since Jones' introduction of this condition into the medical literature. LPD has
been diagnosed in 3-20% of patients who are infertile and in 5-60% of patients experiencing
recurrent pregnancy loss. However, data show that 6-10% of women who are fertile
demonstrate an inadequate luteal phase, which confirms the need for a better understanding
of normal variations in the menstrual cycle and in variations that could be pathologic.

This article addresses healthy menstrual physiology, the proposed pathophysiology of LPD,
current methods available for diagnosis and treatment, and reasons for the controversy
surrounding this subject.

Healthy menstrual physiology

Following ovulation, the mature ovarian follicle forms the corpus luteum, which becomes a
blood-filled structure that allows the precursor cholesterol to be obtained, initiating
steroidogenesis and resulting in progesterone production. Whereas the follicular phase of the
menstrual cycle can vary in length, the secretory phase lasts approximately 14 days,
correlating with the life span of the corpus luteum. Presumably, progesterone prepares the
endometrium for implantation and maintenance of a pregnancy. If pregnancy occurs, the
production of progesterone from the corpus luteum continues for 7 weeks because of the
tonic release of luteinizing hormone (LH) from the pituitary gland. Studies show that after 7
weeks, the placenta takes over this function. If pregnancy does not occur, menses begins with
the demise of the corpus luteum.

For related information, see Medscape's Pregnancy Resource Center.

Pathophysiology
The following mechanisms can cause an inadequate endometrial response to hormonal
stimulation during the luteal phase. [4]

Abnormal follicular development

Abnormal follicular development results from inadequate follicle-stimulating hormone (FSH)

and luteinizing hormone (LH) secretion from the anterior pituitary gland. FSH stimulates the
granulosa cells of the developing follicle to produce estradiol from the conversion of its
substrate androstenedione. A decrease in FSH release results in reduced granulosa cell
growth and lower estradiol levels. Because the corpus luteum is not a de novo structure but is
a direct result of the follicle, it shows the effects of abnormal folliculogenesis with decreased
progesterone production.

Abnormal luteinization
An inadequate LH release can cause a decrease in androstenedione from the theca cells. Less
substrate results in a decrease in estradiol and, subsequently, lower progesterone levels.
Additionally, a suboptimal LH surge at ovulation causes deficient progesterone because of
inadequate luteinization of the granulosa cells.

Uterine abnormalities

Uterine abnormalities cause changes in vascularization of the endometrium despite normal

progesterone levels. Myomas, uterine septa, and endometritis are responsible for poor
secretory changes in the endometrium.

Hypocholesterolemia

Hypocholesterolemia is the substrate responsible for initiation of the steroid pathway. A

deficiency results in low-to-absent progesterone production and a luteal phase defect.

Epidemiology
Frequency

United States

No consensus has been achieved regarding frequency; however, a 1991 symposium

hypothesized that luteal phase deficiency (LPD) occurs in 3-10% of infertile patients, and
healthy women have deficient luteal phase production of progesterone on a sporadic basis.

International

Presumably, international frequency is similar to that in the United States.

Mortality/Morbidity

No morbidity or mortality has been associated with this condition.

Race

Luteal phase deficiency affects women of all races.

Sex

Luteal phase deficiency affects only women.

Age

Luteal phase deficiency primarily affects women during their reproductive years.

History
The patient may report menstrual cycles of less than 26 days or a luteal phase of less than 11
days by basal body temperatures; however, neither of these circumstances can alone be used
to diagnose luteal phase deficiency.

Physical
Physical findings that might aid in the diagnosis of luteal phase dysfunction are those
associated with abnormal endocrine function.

An enlarged thyroid gland is indicative of hypothyroidism.

Expression of milk from the breasts (galactorrhea) is indicative of hyperprolactinemia.
An enlarged, irregularly shaped uterus is indicative of uterine myomas.

Causes
See Pathophysiology for a full discussion of the causes.

Differential Diagnoses
Hyperprolactinemia
Polycystic Ovarian Syndrome
Thyroid Disease

Laboratory Studies
See the list below:

Serum progesterone levels have been studied as a means to diagnose luteal phase
deficiency (LPD). Early data showed that peak progesterone production occurred in
the mid-luteal phase. Later studies confirmed that progesterone is released in a
pulsatile fashion, suggesting that a single sample is nondiagnostic. The use of multiple
samples to overcome the pulsatile nature of progesterone is expensive and
inconvenient.
Urinary LH kits provide a useful test to estimate the appropriate timing of an
endometrial biopsy (EB). Following a positive test finding, ovulation occurs within
24-26 hours. The EB should be performed on the 12th day of a 14-day luteal phase.
Studies measuring progestin endometrial protein (PEP) have not been conclusive in
diagnosing LPD. Studies regarding cell adhesion molecules or integrins, growth
factors, and cytokines are all in the experimental phase.

Imaging Studies
Ultrasound documentation of ovulation from follicular growth to collapse of the follicle is
very accurate; however, this procedure is too expensive and time consuming to be realistic in
all patients. [5] Ultrasound measurement of endometrial thickness has not been shown to be
effective in the prediction of luteal phase deficiency.
Procedures
See the list below:

Biopsy
o In 1950, Noyes, Hertig, and Rock established that the diagnosis of luteal phase
deficiency (LPD) is centered on histologic dating of the endometrium.
However, the location and time of the biopsy can greatly influence
endometrial biopsy (EB) findings. Some authors believe that mid-luteal phase
biopsy is the best for accurate diagnosis of LPD.
o Biopsies from the fundus of the uterus yield improved histologic samples
compared to those taken from the lower uterine segment. Specimens taken
approximately 1-2 days prior to menses provide better specimens for
interpretation. For example, women with cycles of 28 days should have an EB
performed on the 26th day.
o Histologically, a luteal phase defect provides a biopsy that lags behind the date
of actual endometrial sampling by 3 days or more. To confirm that such a
result is not a variance within the reference range, the biopsy should be
performed in 2 consecutive cycles; however, the discomfort associated with
the biopsy causes difficulty in convincing the patient to have the procedure
performed twice. Several methods can be used to time the EB just prior to
menses. The basal body temperature (BBT) chart is one such method.
The BBT chart can aid in determining the length of the luteal phase. A
luteal phase of less than 11 days may be associated with LPD.
The BBT chart can also assist in timing the EB by observing the
patient's cycle length and performing the biopsy 2 days prior to the
expected menses.
Although the BBT chart is easy and inexpensive, interpretation can be
difficult and frustrating with a woman who is infertile or has suffered
multiple pregnancy losses.

Medical Care
See the list below:

Hyperprolactinemia and hypothyroidism cause luteal phase deficiency (LPD) through

hypothalamic-pituitary dysfunction.
Bromocriptine and levothyroxine, respectively, are used to treat LPD in women with
these conditions.
In women without hyperprolactinemia and hypothyroidism, vaginal progesterone is
advocated to supplement endogenous progesterone production. The vaginal
suppository or gel is preferred over both the oral and intramuscular forms because of
superior endometrial progesterone concentrations. Vaginal suppositories are less
expensive but are messier than the vaginal gel. Progesterone should be continued for
8-10 weeks to cover the time of the ovarian-placental shift.
A Cochrane review found that synthetic progesterone is preferred to micronized
progesterone. The study also found that other substances, such as estrogen and human
chorionic gonadotropin (hCG), did not improve outcomes. No specific route or
duration was preferred. [6]
 Clomiphene citrate corrects LPD by improving folliculogenesis and the resultant
luteal phase following ovulation. Successful treatment with gonadotropins and HCGs
probably results from superovulation rather than from a correction of LPD.
Following any of these treatments, the patient should have a repeat endometrial
biopsy to determine that LPD has been corrected.

Medication Summary
The goals of pharmacotherapy in luteal phase deficiency are to restore ovarian function,
reduce morbidity, and prevent complications.

Hormone replacements
Class Summary

Medical treatment centers on hormonal support of the patient's luteal phase.

Bromocriptine (Parlodel)

View full drug information

Used if hyperprolactinemia is the underlying pathology causing LPD. Tablets can be used
vaginally in patients who cannot tolerate adverse GI effects.

Levothyroxine (Levoxyl, Synthroid)

View full drug information

If LPD is caused by hypothyroidism, correction of endocrine disease results in normal luteal

phase.

Clomiphene citrate (Clomid, Serophene)

View full drug information

Stimulates release of pituitary gonadotropins. Improves folliculogenesis and, therefore, the

luteal phase. Works best in biopsies that are lagging 1 week behind the date of endometrial
sampling.

Cabergoline (Dostinex)

View full drug information

Long-acting dopamine receptor agonist with high affinity for D2 receptors. Prolactin
secretion by anterior pituitary predominates under hypothalamic inhibitory control exerted
through dopamine.

Progesterone intravaginal gel

 View full drug information

Progesterone supplementation may be administered PO, IM, or vaginally. Oral progesterone

is metabolized rapidly in liver, and the metabolites have little effect on endometrial activity.
When administered IM, fails to achieve adequate levels of endometrial progesterone
compared with vaginal forms. Vaginal progesterone is DOC for LPD; this is because of the
proximity of the uterus to where the medication is delivered. Vaginal gel 8%, either qd or bid,
is better tolerated compared to suppository form. Gel also provides increased receptor sites in
the endometrium compared with suppository. Treatment begins 2 days after ovulation as
determined by ovulation predictor kit. Correction of LPD can be confirmed by repeat EB.

Follitropins (Follistim, Gonal-F, Fertinex)

Improve folliculogenesis, which increases total progesterone. This remains an expensive

method associated with increased patient discomfort because medication is administered SC.

Further Outpatient Care

All diagnostic testing and treatment can be performed in an outpatient setting.

Further Inpatient Care

Luteal phase dysfunction does not require hospitalization and therefore no inpatient
diagnostic workup or treatment.

Inpatient & Outpatient Medications

See the list below:

Medications used to treat luteal phase dysfunction include dopamine receptor agonists
to treat elevated serum prolactin levels.
Thyroid replacement treats hypothyroidism.
Supplemental progesterone increases the lower levels in the luteal phase observed
with this condition.
Clomiphene citrate enhances follicular development and thus increases luteal-phase
progesterone levels.
Human menopausal gonadotropins enhance follicular development and increase
luteal-phase progesterone levels.

Deterrence/Prevention
No methodology prevents luteal phase defect. Maintain a high level of clinical suspicion that
such a condition exists when seeing a patient with infertility or recurrent pregnancy loss.

Complications
Complications are associated with the endometrial biopsy. Be cautious when performing the
biopsy to avoid perforating the uterus. Advise patients to take a nonsteroidal anti-
inflammatory drug (NSAID) prior to the procedure to alleviate uterine cramping. No
antibiotic prophylaxis is needed.

Prognosis
The lack of double-blinded placebo-controlled studies prevents an accurate prognosis for this
condition. A report by the Practice Committee of the American Society for Reproductive
Medicine concluded that there is no significant evidence that LPD alone can cause infertility.
[7]

Patient Education
Patients should keep an accurate menstrual cycle calendar. Abnormal cycle length may
heighten the physician's suspicion that a luteal phase dysfunction exists.
References

1. Jones GES. Some newer aspects of management of infertility. JAMA. 1949.

141:1123-1129.
2. Siklsi GS, Bnhidy FG, cs N. Fundamental role of folliculo-luteal function in
recurrent miscarriage. Arch Gynecol Obstet. 2012 Nov. 286(5):1299-305. [Medline].
3. Sonntag B, Ludwig M. An integrated view on the luteal phase: diagnosis and
treatment in subfertility. Clin Endocrinol (Oxf). 2012 Oct. 77(4):500-7. [Medline].
4. Boutzios G, Karalaki M, Zapanti E. Common pathophysiological mechanisms
involved in luteal phase deficiency and polycystic ovary syndrome. Impact on
fertility. Endocrine. 2013 Apr. 43(2):314-7. [Medline].
5. Hajishaiha M, Ghasemi-Rad M, Karimpour N, Mladkova N, Boromand F.
Transvaginal sonographic evaluation at different menstrual cycle phases in diagnosis
of uterine lesions. Int J Womens Health. 2011. 3:353-7. [Medline].
6. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal
phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2011
Oct 5. CD009154. [Medline].
7. Practice Committee of the American Society for Reproductive Medicine. Current
clinical irrelevance of luteal phase deficiency: a committee opinion. Fertil Steril. 2015
Apr. 103 (4):e27-32. [Medline].
8. Taylor HS, Bagot C, Kardana A, et al. HOX gene expression is altered in the
endometrium of women with endometriosis. Hum Reprod. 1999 May. 14(5):1328-31.
9. Behrman HR, Endo T, Aten RF. Corpus luteum function and regression. Reprod Med
Rev. 1993. 2:153-80.
10. Cermik D, Selam B, Taylor HS. Regulation of HOXA-10 expression by testosterone
in vitro and in the endometrium of patients with polycystic ovary syndrome. J Clin
Endocrinol Metab. 2003 Jan. 88(1):238-43. [Medline].
11. Cicinelli E, de Ziegler D, Bulletti C, et al. Direct transport of progesterone from
vagina to uterus. Obstet Gynecol. 2000 Mar. 95(3):403-6. [Medline].
12. Cooke ID. The corpus luteum. Hum Reprod. 1988 Feb. 3(2):153-6. [Medline].
13. Csapo AI, Pulkkinen MO, Ruttner B et al. The significance of the human corpus
luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol. 1972
Apr 15. 112(8):1061-7. [Medline].
14. Daftary GS, Taylor HS. Hydrosalpinx fluid diminishes endometrial cell HOXA10
expression. Fertil Steril. 2002 Sep. 78(3):577-80. [Medline].
15. Giudice LC. Growth factors and growth modulators in human uterine endometrium:
their potential relevance to reproductive medicine. Fertil Steril. 1994 Jan. 61(1):1-17.
[Medline].
16. Healy DL, Schenken RS, Lynch A, et al. Pulsatile progesterone secretion: its
relevance to clinical evaluation of corpus luteum function. Fertil Steril. 1984 Jan.
41(1):114-21. [Medline].
17. Jones GS. The luteal phase defect. Fertil Steril. 1976 Apr. 27(4):351-6. [Medline].
18. Karamardian LM, Grimes DA. Luteal phase deficiency: effect of treatment on
pregnancy rates. Am J Obstet Gynecol. 1992 Nov. 167(5):1391-8. [Medline].
19. Li TC, Nuttall L, Klentzeris L, Cooke ID. How well does ultrasonographic
measurement of endometrial thickness predict the results of histological dating?. Hum
Reprod. 1992 Jan. 7(1):1-5. [Medline].
20. McNeely MJ, Soules MR. The diagnosis of luteal phase deficiency: a critical review.
Fertil Steril. 1988 Jul. 50(1):1-15. [Medline].
21. Murray DL, Reich L, Adashi EY. Oral clomiphene citrate and vaginal progesterone
suppositories in the treatment of luteal phase dysfunction: a comparative study. Fertil
Steril. 1989 Jan. 51(1):35-41. [Medline].
22. Noyes RW, Hertig AW, Rock J. Dating the endometrial biopsy. Fertil Steril. 1950.
1:3-25.
23. Peters AJ, Lloyd RP, Coulam CB. Prevalence of out-of-phase endometrial biopsy
specimens. Am J Obstet Gynecol. 1992 Jun. 166(6 Pt 1):1738-45; discussion 1745-6.
[Medline].
24. Peters AJ, Wentz AC. Luteal phase inadequacy. Seminars in Reprod Endo. 1995.
13:162-171.
25. Sherman BM, Korenman SG. Measurement of plasma LH, FSH, estradiol and
progesterone in disorders of the human menstrual cycle: the short luteal phase. J Clin
Endocrinol Metab. 1974 Jan. 38(1):89-93. [Medline].
26. Shoupe D, Mishell DR Jr, Lacarra M, et al. Correlation of endometrial maturation
with four methods of estimating day of ovulation. Obstet Gynecol. 1989 Jan.
73(1):88-92. [Medline].
27. Soules MR. Luteal phase deficiency. Pitkin RM, ed. Clinical Obstetrics and
Gynecology. Philadelphia, PA: JB Lippincott; 1991. Vol 34: 123-126.
28. Yen SC, Jaffe RB, Barbieri RL. Luteal phase defects. Reproductive Endocrinology.
4th ed. 1999. 244-5.
29. Palomba S, Santagni S, La Sala GB. Progesterone administration for luteal phase
deficiency in human reproduction: an old or new issue?. J Ovarian Res. 2015 Nov 19.
8:77. [Medline].